Price Chopper, CDPHP partner to provide health screenings
SCHENECTADY, N.Y. — Price Chopper Supermarkets and CDPHP have joined forces to provide community access to health services and screenings at new health stations, which are located in six Price Chopper locations in Upstate New York.
The stations will provide free blood pressure, weight, heart rate, and blood oxygen and temperature readings. Additionally, patients will have the opportunity to create a Personal Health Assessment that can be printed at the station or at PriceChopper.com.
“These health stations will provide our members unique access to benefits and services at a time and place that’s convenient for them,” Dr. John Bennett, president and CEO, CDPHP said. “As we enter a new era in health care, we are thrilled to partner with Price Chopper Supermarkets, an organization that shares our commitment to community wellness.”
Price Chopper and CDPHP partner on other initiatives, like medication therapy management and immunizations services.
Merck KGaA, National MS Society distribute $1.3 million for early-stage drug research
NEW YORK — Three organizations will receive part of $1.3 million in funding that German drug maker Merck KGaA and the National Multiple Sclerosis Society are distributing for MS research.
EMD Serono, the name the Merck KGaA uses in the United States to avoid confusion with U.S.-based Merck & Co., and the National MS Society said the money will help encourage early-stage drug discovery for the autoimmune disease.
The recipients of the funding are the University of California San Diego School of Medicine, which is receiving $285,000 over 18 months; the Emory University School of Medicine, receiving $471,333 over 21 months; and Euroscreen SA, receiving $501,657 over 12 months.
Amneal launches new GERD treatment
BRIDGEWATER, N.J. — Amneal Pharmaceuticals has launched a new treatment for gastroesophageal reflux disease under a partnership with a South Korean drug maker.
Amneal announced Tuesday the launch of esomeprazole strontium delayed-release capsules in the 49.3-mg strength, which it is marketing in the United States under a contract with Hanmi Pharmaceutical Co. The drug is expected to begin shipping Wednesday in 30-count bottles.
The drug is being marketed as an alternative to AstraZeneca’s Nexium (esomeprazole magnesium), though it received approval from the Food and Drug Administration in August as a branded drug. The drug contains a similar active ingredient to Nexium, but in a different salt form.